

Anti-D immunoglobulin**Section**

Human immunoglobulins

- Parenteral > General injections > IV: 250 µg in single-dose vial
- Parenteral > General injections > IM: 250 µg in single-dose vial

Indications

Maternal care for red cell antibodies

Carbetocin**Section**

Uterotonics

- Parenteral > General injections > IV: 100 µg per mL (heat stable)

Indications

Postpartum haemorrhage

Carboplatin**Section**

Cytotoxic medicines

- Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL

Indications

Other specified carcinomas of ovary

Cisplatin**Section**

Cytotoxic medicines

- Parenteral > General injections > IV: 50 mg per 50 mL; 100 mg per 100 mL; 10 mg per 10 mL; 20 mg per 20 mL

Indications

Malignant neoplasms of cervix uteri

Clomifene**Section**

Ovulation inducers

- Oral > Solid: 50 mg (citrate)

Indications

Female infertility without specification whether primary or secondary

Copper-containing intrauterine device**Section**

Intrauterine devices

- -

Indications

Contact with health services for insertion of contraceptive device

Dexamethasone

Section

Other medicines administered to the mother

- Parenteral > General injections > unspecified: 4 mg per mL (dexamethasone phosphate (as sodium))

Indications

Respiratory distress syndrome of the newborn, altered by maternal corticosteroid therapy

Ergometrine

Section

Uterotonics

- Parenteral > General injections > unspecified: 200 µg in 1 mL ampoule (hydrogen maleate)

Indications

Postpartum haemorrhage

Estradiol cypionate + medroxyprogesterone acetate

Section

Injectable hormonal contraceptives

- Parenteral > General injections > IM: 5 mg + 25 mg

Indications

Contact with health services for reasons associated with reproduction

Ethinylestradiol + etonogestrel

Section

Intravaginal contraceptives

- Local > Vaginal > vaginal ring: 2.7 mg + 11.7 mg

Indications

Contact with health services for contraceptive management

Ethinylestradiol + levonorgestrel

Section

Oral hormonal contraceptives

- Oral > Solid: 50 µg + 250 µg [4]
- Oral > Solid: 30 µg + 150 µg

Indications

Contact with health services for postcoital contraception

Contact with health services for contraceptive management

Ethinylestradiol + norethisterone

Section

Oral hormonal contraceptives

- Oral > Solid: 35 µg + 1 mg

Indications

Contact with health services for contraceptive management

Etonogestrel-releasing implant

Section

Implantable contraceptives

- Implant > Subdermal: 68 mg single rod

Indications

Contact with health services for insertion of contraceptive device

Folic acid

Section

Antianaemia medicines

- Oral > Solid: 400 µg

Indications

Cephalocele

Anencephaly or similar anomalies

Spina bifida

Levonorgestrel

Section

Oral hormonal contraceptives

- Oral > Solid: 750 µg [2]; 1.5 mg [1]
- Oral > Solid: 30 µg

Intrauterine devices

- Intrauterine system with reservoir containing 52 mg of levonorgestrel.

Indications

Contact with health services for postcoital contraception

Contact with health services for contraceptive management

Contact with health services for insertion of contraceptive device

Levonorgestrel-releasing implant

Section

Implantable contraceptives

- Implant > Subdermal: 75 mg per rod (two-rods)

Indications

Contact with health services for insertion of contraceptive device

Medroxyprogesterone acetate

Section

Injectable hormonal contraceptives

- Parenteral > General injections > IM: 150 mg per mL in 1 mL vial
- Parenteral > General injections > SC: 104 mg per 0.65 mL in pre-filled syringe; 104 mg per 0.65 mL in single dose injection delivery system

Progestogens

- Oral > Solid: 5 mg

Indications

Contact with health services for reasons associated with reproduction

Excessive menstruation with irregular cycle

Methyldopa

Section

Antihypertensive medicines

- Oral > Solid: 250 mg

Indications

Gestational hypertension

Methylergometrine

Section

Uterotonics

Indications

Therapeutic equivalent to [ergometrine](#) pour

Postpartum haemorrhage

Mifepristone - misoprostol

Section

Medicines for medical abortion

- Oral > Solid > tablet: 200 mg + 200 µg; 200 mg [1] + 200 µg [4] in co-package

Indications

Unspecified time of fetal death, cause not specified

Induced abortion

Misoprostol

Section

Uterotonics

- Local > Vaginal > tablet: 25 µg
- Oral > Solid: 200 µg

Medicines for medical abortion

- Oral > Solid > tablet: 200 µg

Indications

Unspecified obstetric condition

Postpartum haemorrhage

Spontaneous abortion, incomplete, without complication

Multiple micronutrient supplement

Section

Other medicines administered to the mother

- Tablet containing:
- Vit A: 800 mcg retinol activity equivalent
- Vit C: 70 mg
- Vit D: 5 mcg (200 IU)
- Vit E: 10 mg alpha tocopherol equivalent
- Vit B1: 1.4 mg
- Vit B2: 1.4 mg
- Vit B3: 18 mg niacin equivalent
- Vit B6: 1.9 mg
- Folic acid: 400 mcg
- Vit B12: 2.6 mcg
- Iron: 30 mg
- Iodine: 150 mcg
- Zinc: 15 mg
- Selenium: 65 mcg
- Copper: 2 mg

Indications

Maternal care for other specified conditions predominantly related to pregnancy

Nifedipine

Section

Antioxytocics (tocolytics)

- Oral > Solid: 10 mg (immediate-release)

Indications

Preterm labour without delivery

Norethisterone

Section

Oral hormonal contraceptives

- Oral > Solid: 350 µg

Progestogens

Indications

Contact with health services for contraceptive management

Therapeutic equivalent to medroxyprogesterone acetate pour

Excessive menstruation with irregular cycle

Norethisterone enantate

Section

Injectable hormonal contraceptives

- Parenteral > General injections > IM: 200 mg per mL in 1 mL ampoule oily solution

Indications

Contact with health services for reasons associated with reproduction

Oxytocin

Section

Uterotonics

- Parenteral > General injections > unspecified: 10 IU per mL

Indications

Postpartum haemorrhage

Progesterone vaginal ring

Section

Intravaginal contraceptives

- Local > Vaginal > vaginal ring: 2.074 g micronized progesterone

Indications

Contact with health services for contraceptive management

Simvastatin

Section

Medicines for endocrine disorders

- Oral > Solid: 20 mg

Indications

Polycystic ovary syndrome

Sulfadoxine + pyrimethamine

Section

Antimalarial medicines > Medicines for chemoprevention

- Oral > Solid: 500 mg + 25 mg tablet

Indications

Malaria due to Plasmodium falciparum

Tranexamic acid

Section

Other medicines administered to the mother

- Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule

Indications

Postpartum haemorrhage

Ulipristal

Section

Oral hormonal contraceptives

- Oral > Solid: 30 mg tablet (ulipristal acetate)

Indications

Contact with health services for postcoital contraception